WY vs PCH vs RYN

For growth investors, PotlatchDeltic Corporation (PCH) is the stronger pick with 3.

7% revenue growth year-over-year, versus -61. 6% for Rayonier Inc. (RYN). Rayonier Inc. (RYN) offers the better valuation at 48. 2x trailing P/E (56. 1x forward), making it the more compelling value choice. Analysts rate Weyerhaeuser Company (WY) a "Buy" — based on 25 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Rayonier Inc.

(RYN) is the cheapest at 48. 2x versus PotlatchDeltic Corporation at 149. 0x. On forward P/E, PotlatchDeltic Corporation is actually cheaper at 53. 8x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, PotlatchDeltic Corporation (PCH) delivered a total return of -9.

6%, compared to -21. 3% for Weyerhaeuser Company (WY). Over 10 years, the gap is even starker: PCH returned +94. 0% versus WY's +15. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Rayonier Inc.

(RYN) is the lower-risk stock at 0. 40β versus PotlatchDeltic Corporation's 0. 75β — meaning PCH is approximately 88% more volatile than RYN relative to the S&P 500. On balance sheet safety, Rayonier Inc. (RYN) carries a lower debt/equity ratio of 48% versus 59% for Weyerhaeuser Company — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), PotlatchDeltic Corporation (PCH) is pulling ahead at 3.

7% versus -61. 6% for Rayonier Inc. (RYN). On earnings-per-share growth, the picture is similar: Weyerhaeuser Company grew EPS -16. 7% year-over-year, compared to -81. 6% for Rayonier Inc.. Over a 3-year CAGR, PCH leads at -7. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Rayonier Inc.

(RYN) is the more profitable company, earning 97. 9% net margin versus 2. 1% for PotlatchDeltic Corporation — meaning it keeps 97. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RYN leads at 17. 2% versus 3. 1% for PCH. At the gross margin level — before operating expenses — RYN leads at 32. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, PotlatchDeltic Corporation (PCH) trades at 53.

8x forward P/E versus 84. 8x for Weyerhaeuser Company — 31. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RYN: 31. 0% to $27. 75.

All stocks in this comparison pay dividends.

Rayonier Inc. (RYN) offers the highest yield at 8. 7%, versus 3. 5% for Weyerhaeuser Company (WY).

For long-horizon retirement investors, Rayonier Inc.

(RYN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 40), 8. 7% yield). Both have compounded well over 10 years (RYN: +39. 8%, PCH: +94. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Real Estate sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.